Vhernie Manickavasagar

Vhernie is a Capital Markets Partner with 20 years of experience advising companies on Initial Public Offerings (IPOs), Special Purpose Acquisition Companies (SPACs), Mergers and Acquisitions (including City Code offers), Demergers and Further Offerings on the UK stock exchanges. Vhernie is our UK IPO Leader and authors IPO Watch EMEA, which explores the major trends and market activity within the European, Middle East and African IPO markets.

Vhernie also spent three years in PwC New York with our US Capital Markets team working on US IPOs, Mergers and Acquisitions and Demergers and has worked on a number of capital markets deals which included consideration of both UK and US stock exchanges.

Vhernie has a wide industry experience and also leads our Health, Pharmaceutical & Life Sciences industry team.

A selection of announced deals Vhernie has worked on include:

• Abbvie, Inc.'s $63bn acquisition of Allergan Plc
• $32bn Class 1 acquisition of Baxalta, Inc. by Shire plc
• $25bn+ global asset swap (oncology, vaccines, consumer) between GSK and Novartis and subsequent GSK $13bn buy out of Novartis stake in Consumer Health JV
• $1.25bn SPAC IPO of J2 Acquisition on London Main Market
• $500m SPAC IPO of Landscape and subsequent $830m reverse acquisition of APW, LLC
• Merger of Sorin SpA and Cyberonics, Inc. as Livanova plc and London listing
• FirstGroup plc £500m Return of Capital
• Equinix Inc.'s $3.7bn offer for Telectiy Group plc under the City Code
• Marshalls plc £535m class 1 acquisition of Marley
• Spin off of Mead Johnson from Bristol Myers Squibb (together with Convatec disposal) on NYSE
• Rights Issues by Lloyds Banking Group (£13.5bn), National Grid (£3.2bn), Wolseley (£1bn), GKN (£423m), Rexam (£350m) and Galliford Try (£158m)